2022 Annual Meeting | C120 - Multiple Sclerosis Disease-modifying Treatment
Date
Wednesday 04/06/22
Time
07:00 AM - 09:00 AM PDT
Add To Calendar
Session Format
This program will be presented both in-person and online
On Demand
This program will be available in the meeting's On Demand product.
Event Type
Seminar
Director(s)
Jacqueline Bernard, MD, FÂ鶹´«Ã½Ó³»
Topic(s)
Multiple Sclerosis
Learning Objectives
Participants should be comfortable with selecting DMTs based on risk stratification, including pregnancy and family planning for RRMS, SPMS, and PPMS; understand complications associated with approved DMTs in RRMS, SPMS, and PPMS; creating an algorithm for patients who break through therapies and no longer meet "NEDA" criteria; and the impact of COVID-19 disease and vaccination on DMT doses.
CME Available
2.00 CME credits
Core Competencies
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement
Program Level
Intermediate
Recommended Audience
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student
Teaching Styles
Didactic
Program Materials
Program Evaluations
Event Timeline
07:00 AM - 09:00 AM PDT
Speaker
Multiple Sclerosis Disease-modifying Treatment
07:00 AM - 07:00 AM PDT
Speaker
Walk-in Slides
Faculty Disclosures
Jacqueline Bernard, MD, FÂ鶹´«Ã½Ó³»
Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for 2ND MD. Dr. Bernard has received publishing royalties from a publication relating to health care.
Michael A. Lane, MD
Dr. Lane has nothing to disclose.